As per DelveInsight’s assessment, The increasing importance of precision medicine in cancer treatment is driving up the demand for liquid biopsy in cancer diagnoses. The idea of “precision medicine” or tailoring the treatment strategy to the biological characteristics of the tumor is seen as a new method for managing cancer. Precision medicine has a wide range of clinical applications, including screening, diagnosis, prognosis, therapy response and resistance prediction, early recurrence/metastasis detection, and biologic cancer stratification.

DelveInsight’s “Liquid Biopsy in Cancer Diagnostics Market” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.  The report also covers the major emerging products and key Liquid Biopsy in Cancer Diagnostics companies actively working in the market.

Liquid Biopsy in Cancer Diagnostics

A liquid biopsy is a blood test that finds cancerous cells or cancerous DNA, often known as “circulating tumour DNA” or “ctDNA,” that are moving about in the blood. Cancer cells also expire and are replaced, just like healthy ones. These decomposing dead cells are discharged from the tumor into the bloodstream as they decompose.

DelveInsight Liquid Biopsy in Cancer Diagnostics Market Analysis: The Global Liquid Biopsy in Cancer Diagnostics market size was valued approximately USD 7.64 Billion in 2022 and is anticipated to reach USD 19.24 Billion with a CAGR of 16.24% during the forecasted period (2023-2028)

Liquid Biopsy in Cancer Diagnostics Market Insights

Geographically, The market for liquid biopsy for cancer diagnosis is anticipated to be dominated by North America. According to estimates, North America will hold the largest market share due to the region’s favorable environment for product development and launches, rising oncology research emphasis, rising cancer prevalence, and supportive government policies promoting liquid biopsy research.

To know more about why North America is leading the market growth in the Liquid Biopsy in Cancer Diagnostics market, get a snapshot of the report Liquid Biopsy in Cancer Diagnostics Market Forecast

Recent Developments in the Liquid Biopsy in Cancer Diagnostics Market Report

• In October 2021, A novel liquid biopsy test for the identification of Minimal Residual Disease (MRD) in Acute Myeloid Leukaemia (AML) was created by Sysmex Inostics and validated by the CLIA. The ultra-sensitive Plasma-Safe-SeqS technology NGS tests offered by Sysmex Inostics’ CLIA lab services in Baltimore, Maryland, in the United States, now include the AML-MRD-SEQ test
• In June 2021, Inivata Ltd., a Cambridge, England-based startup with a global commercial stage liquid biopsy technology, was acquired by NeoGenomics
• In January 2021, Thrive Earlier Detection Corp. (“Thrive”), a healthcare organisation focused on creating a blood-based, multi-cancer screening test, was purchased by Exact Sciences Corporation
• Thus, owing to such developments in the market, rapid growth will be observed in the Liquid Biopsy in Cancer Diagnostics market during the forecast period

To read more about the latest highlights related to Liquid Biopsy in Cancer Diagnostics, get a snapshot of the key highlights entailed in the Liquid Biopsy in Cancer Diagnostics

Key Liquid Biopsy in Cancer Diagnostics companeis in the Market

Some of the key Liquid Biopsy in Cancer Diagnostics companies operating in the market include-  Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd.,and others.

Liquid Biopsy in Cancer Diagnostics Market Analysis

Additionally, the rising incidence of lifestyle disorders, which operate as important cancer development risk factors. For instance, according to data from the Global Obesity Observatory (2022), Mexico has an 8 on a scale of 10 national risk of developing obesity. This indicates that the majority of people in Mexico are either in the obese population or are very likely to become fat in the near future. Excess body fat has been linked to a higher risk of developing a number of malignancies, including colorectal, postmenopausal breast, uterine, esophageal, kidney, and pancreatic cancers, according to numerous studies. Cancer incidence is also thought to be influenced by the country’s growing older population. So, during the projected period, the market for Liquid Biopsy in Cancer Diagnostics is anticipated to continue expanding (2023-2028).

Scope of the Liquid Biopsy in Cancer Diagnostics Market Report

• Coverage: Global
• Study Period: 2020–2028
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Product Type: Instruments And Reagents & Kits, and Services
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Sample Type: Blood, Urine, and Saliva
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Biomarker Type: Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Cancer Type: Lung Cancer, Breast Cancer, Colon Cancer, and Others
• Liquid Biopsy in Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Liquid Biopsy in Cancer Diagnostics Companies: Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the Liquid Biopsy in Cancer Diagnostics market are set to emerge as the trendsetter explore @ Liquid Biopsy in Cancer Diagnostics Companies

Table of Contents 

Interested in knowing how the Liquid Biopsy in Cancer Diagnostics market will grow by 2028? Click to get a snapshot of the Liquid Biopsy in Cancer Diagnostics Market Analysis

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services